ClinicalTrials.gg
CompletedNCT04744831DESTINY-CRC02Updated Jan 14, 2026Results posted

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

A Phase 2 interventional study of DS-8201a 5.4 mg/kg Q3W and DS-8201a 6.4 mg/kg Q3W in Advanced Colorectal Cancer, sponsored by Daiichi Sankyo. Completed at 63 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Daiichi Sankyo · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Colorectal Neoplasms by Daiichi Sankyo — 1 open to participants now, 1 under way, none of them phase 3. Colorectal Neoplasms · Daiichi Sankyo.

Enrollment
3rd of 12
122 · median 85
Started
2021
the only one that year
Phase 2
7 of 14
none open now
Registered
13th of 14
by date

Among the 14 studies in Colorectal Neoplasms by Daiichi Sankyo, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 13th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 14 studies in Colorectal Neoplasms by Daiichi Sankyo is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Colorectal Neoplasms by Daiichi Sankyo, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).

Read the detailed description

This 2-stage study will evaluate participants with locally advanced, unresectable, or metastatic HER2-overexpressing colorectal cancer (CRC) (immunohistochemistry [IHC] 3+ or IHC 2+/ in situ hybridization [ISH]+) of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) wild-type and either rat sarcoma viral oncogenes homologue (RAS) wild-type or mutant tumor type, previously treated with standard therapy. In the first stage, participants will be randomized 1:1 with 2 doses of T-DXd. After Stage 1 enrollment is complete, all further eligible participants will be registered to T-DXd administered IV in Stage 2. Participants will receive the assigned dose of T-DXd until progression of disease or the participant meets one of the discontinuation criteria.

03

Conditions studied

  • Advanced Colorectal Cancer

Keywords

  • Metastatic Colorectal Cancer
  • HER2 Overexpressing Colorectal Cancer
  • BRAF Wild-Type Status
  • DS-8201a
  • Trastuzumab deruxtecan
  • Advanced Colorectal Cancer
  • T-DXd
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

KEY Inclusion Criteria:

Participants must meet all of the following criteria to be eligible for randomization/registration into the study:

  1. Adults aged ≥20 years in Japan, Taiwan, and Korea, or those aged ≥18 years in other countries, at the time the Forms (ICFs) are signed.
  2. -documented, unresectable, recurrent, or colorectal adenocarcinoma. Participants must have v-raf murine sarcoma viral oncogene homologue B1 (BRAF) wild-type cancer and rat sarcoma viral oncogenes homologue (RAS) status identified in primary or metastatic site.
  3. The following therapies should be included in :

    1. Fluoropyrimidine, oxaliplatin, and irinotecan, unless
    2. Anti-epidermal growth factor receptor (EGFR) treatment, if RAS wild-type and if clinically indicated
    3. Anti-vascular endothelial growth factor (VEGF) treatment, if clinically indicated
    4. Anti-programmed death ligand 1 (PD-(L)-1) therapy, if the tumor is microsatellite instability (MSI)-high/deficient mismatch repair (dMMR), or tumor mutational burden (TMB)-high, if clinically indicated
  4. Confirmed human epidermal growth factor 2 ()-overexpressing status assessed by central laboratory and defined as immunohistochemistry (IHC) 3+ or IHC 2+/ in situ hybridization (ISH) +.
  5. Presence of at least one assessed by the Investigator per (RECIST) version 1.1.
  6. Performance Status (ECOG PS) of 0 or 1.
  7. Has (LVEF) ≥50% within 28 days before randomization/registration.

KEY Exclusion Criteria:

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Medical history of myocardial infarction (MI) within 6 months before randomization/registration, symptomatic congestive heart failure (CHF) ( Class II to IV). Participants with troponin levels above the (ULN) at Screening (as defined by the manufacturer), and without any MI-related symptoms, should have a cardiologic consultation before randomization/registration to rule out MI.
  2. Has a interval corrected with Fridericia's formula (QTcF) prolongation to >470 msec (female participants) or >450 msec (male participants) based on the average of the Screening triplicate 12-lead (ECGs).
  3. Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
  4. Lung-specific intercurrent illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within 3 months of the randomization/registration, severe asthma, severe [COPD], restrictive lung disease, pleural effusion, etc.).
  5. Any , connective tissue, or inflammatory disorders (eg, rheumatoid arthritis, Sjögren syndrome, sarcoidosis, etc.) where there is documented, or a suspicion of, pulmonary involvement at the time of Screening.
  6. Prior pneumonectomy.
  7. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive may be included in the study. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole-brain radiotherapy and randomization/registration.
  8. Participants with .
  9. Has known (HIV) infection.
  10. Active and/or infection, such as those with serologic evidence of viral infection within 28 days before study randomization/registration. Participants with past or resolved hepatitis B virus (HBV) infection are eligible if hepatitis B surface antigen (HBsAg) negative (-) and antibody to hepatitis B core antigen (anti-HBc) positive (+).

    Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).

  11. Previous treatment with a DXd-containing antibody-drug conjugate (ADC).
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    T-DXd 5.4 mg/kg Q3W

    Participants will be randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).

    Drug: DS-8201a 5.4 mg/kg Q3W

  • Experimental
    T-DXd 6.4 mg/kg Q3W

    Participants will be randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).

    Drug: DS-8201a 6.4 mg/kg Q3W

Interventions

  • DrugDS-8201a 5.4 mg/kg Q3W

    Drug page: Trastuzumab deruxtecan

    DS-8201a for injection will be administered intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W)

    Also known as: T-DXd

  • DrugDS-8201a 6.4 mg/kg Q3W

    Drug page: Trastuzumab deruxtecan

    DS-8201a for injection will be administered intravenously (IV) at a dose of 6.4 mg/kg every 3 weeks (Q3W)

    Also known as: T-DXd

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer

    Confirmed objective response rate (ORR), defined as the number (percentage) of participants with complete response (CR) or partial response (PR), were assessed by blinded independent central review (BICR) based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: 6 months post-dose administration to data cut off, up to 20 months

Secondary outcomes

  1. Confirmed Objective Response Rate by Investigator Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer

    Confirmed objective response rate (ORR), defined as the number (percentage) of participants with complete response (CR) or partial response (PR), were assessed by Investigator assessment based on RECIST version 1.1. CR was defined as the disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. ORR was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: From first dose administration to data cut off, up to approximately 19 months

  2. Duration of Response Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer

    DoR, defined as time from the initial response (CR or PR) by BICR and Investigator assessment until documented tumor progression or death from any cause. DoR was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: From the first documented evidence of a response (complete or partial) until disease progression or death, up to approximately 19 months.

  3. Disease Control Rate Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) -Overexpressing Metastatic Colorectal Cancer

    Disease Control Rate (DCR), defined as the proportion of subjects who achieved CR, PR, or SD for a minimum of 6 weeks during study treatment; DCR based on BICR and DCR based on Investigator assessments assessed according to RECIST version 1.1. DCR was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: From first dose administration to data cut off, up to approximately 19 months.

  4. Clinical Benefit Rate Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) -Overexpressing Metastatic Colorectal Cancer

    Clinical Benefit Rate (CBR), defined as proportion of subjects who achieved CR, PR, or SD for at least 6 months; CBR based on BICR and CBR based on Investigator assessments will both be determined based on RECIST version 1.1. CBR was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: From first dose administration to data cut off, up to approximately 19 months.

  5. Progression Free Survival Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer

    Progression Free Survival (PFS) defined as the time from date of randomization/registration until first objective radiographic tumor progression or death from any cause, based on BICR and Investigator assessment according to RECIST version 1.1. PFS was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: From randomization to data cut off, up to approximately 19 months.

  6. Overall Survival Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer

    Overall Survival (OS) defined as the time from date of randomization/ registration until death from any cause, according to RECIST version 1.1. OS was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: From randomization to data cut off, up to approximately 19 months.

  7. Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer

    A Treatment-emergent Adverse Events (TEAE) is defined as an AE that occurs, having been absent before the first dose of study drug or has worsened in severity or seriousness after initiating the study drug until 47 days after the last dose of the study drug. Serious AEs with an onset or worsening 48 days or more after the last dose of study drug, if considered related to study treatment. are also TEAEs. TEAEs were assessed in the Safety Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: From first dose administration to data cut off, up to approximately 19 months.

  8. Serum Concentration of T-DXd

    Descriptive statistics will be provided for serum concentration data of T-DXd, DXd, and total anti-HER2 antibody. Serum concentrations were assessed in the Pharmacokinetics Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: C1D1 (Before infusion (BI), end of infusion (EOI) and 5 hours after infusion), C1D8 (7 days after infusion), C1D15 (14 days after infusion), C2D1 (BI and EOI), C3D1 (BI and EOI), C4D1, (BI and EOI), C6D1 (BI and EOI)

  9. Serum Concentration of Total Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Antibody

    Descriptive statistics will be provided for serum concentration data of T-DXd, DXd, and total anti-HER2 antibody. Serum concentrations were assessed in the Pharmacokinetics Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: C1D1 (Before infusion (BI), end of infusion (EOI) and 5 hours after infusion), C1D8 (7 days after infusion), C1D15 (14 days after infusion), C2D1 (BI and EOI), C3D1 (BI and EOI), C4D1, (BI and EOI), C6D1 (BI and EOI)

  10. Serum Concentration of Active Metabolite MAAA-1181a

    Descriptive statistics will be provided for serum concentration data of T-DXd, DXd, and total anti-HER2 antibody. Serum concentrations were assessed in the Pharmacokinetics Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: C1D1 (Before infusion (BI), end of infusion (EOI) and 5 hours after infusion), C1D8 (7 days after infusion), C1D15 (14 days after infusion), C2D1 (BI and EOI), C3D1 (BI and EOI), C4D1, (BI and EOI), C6D1 (BI and EOI)

  11. Percentage of Participants Positive for Treatment-emergent Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (NAb) in Participants Who Were Administered T-DXd

    Immunogenicity will be assessed through characterization of incidence and titer of Anti-drug Antibodies (ADAs), the number and percentage of subjects positive for NAb of T-DXd by dose level will also be determined. ADAs and NAbs were assessed in the Immunogenicity Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: From baseline to data cut off, up to approximately 19 months

Other outcomes

  1. Change From Baseline in Patient-Reported Outcomes (PROs) in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30)

    Exploratory outcome, results not included in this submission. The QLQ-C30 is composed of both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items and no item occurs in more than 1 scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Patient questionnaires were assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

    Time frame: From baseline to data cut off, up to approximately 19 months.

  2. Change From Baseline in Patient-Reported Outcomes (PROs) in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Colorectal Cancer 29 (QLQ-CR29)

    Exploratory outcome, results not included in this submission. EORTC QLQ-CR29 is designed to be administered in addition to EORTC QLQ-C30. The EORTC QLQ-CR29 is a specific questionnaire for Colorectal Cancer. Scale from 0 to 100, A higher scale represents better function and a higher quality of life.

    Time frame: From baseline to data cut off, up to approximately 19 months

  3. Patient-Reported Outcomes (PROs) in the EuroQol Questionnaire (EQ) of 5 Dimensions (5D) on a Standardized 5- Level (5L) Descriptive Health Status Scale (EQ-5D-5L)

    Exploratory outcome, results not included in this submission. The EQ-5D-5L is self-administered and consists of 2 parts, the EQ-5D-5L descriptive system and the EQ-visual analogue scale. On each dimension, a score of 1 indicates no patient problems in that dimension, 2 indicates slight problems in that dimension, 3 indicates moderate problems in that dimension, 4 indicates severe problems in that dimension and 5 indicates extreme problems in that dimension.

    Time frame: From baseline to data cut off, up to approximately 19 months

  4. Patient-Reported Outcomes (PROs) in Patient's Global Impression of Treatment Tolerability (PGI-TT)

    Exploratory outcome, results not included in this submission. The PGI-TT item is included to assess how a patient perceives the overall tolerability of the study treatment over the past 7 days. This is a single-item questionnaire, and patients will rate the bother associated with any treatment-related symptoms using response options ranging from "Not at all" to "Very much".

    Time frame: From baseline to data cut off, up to approximately 19 months

  5. Patient-Reported Outcomes (PROs) in Patient Global Impression of Symptom Severity (PGIS)

    Exploratory outcome, results not included in this submission. The PGIS item is included to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. This is a single-item questionnaire, and patients will choose the response that best describes the severity of their overall cancer symptoms with options ranging from "No Symptoms" to "Very Severe".

    Time frame: From baseline to data cut off, up to approximately 19 months

  6. Patient-Reported Outcomes (PROs) in Patient Global Impression of Symptom Severity (PGIC)

    Exploratory outcome, results not included in this submission. The PGIC item is included to assess how a patient perceives their overall change in health status since the start of study treatment. This is a single-item questionnaire, and patients will choose from response options ranging from "Much Better" to "Much Worse".

    Time frame: From baseline to data cut off, up to approximately 19 months

  7. Inpatient Healthcare Resource Utilization

    Exploratory outcome, results not included in this submission. The impact of treatment and disease on healthcare resource use (including inpatient admissions, intensive care unit admissions, and length of stay in hospital) will be captured/collected in this study on an event-driven basis.

    Time frame: From baseline to data cut off, up to approximately 19 months

07

Results

Posted Jan 2, 2024

Participant flow

A total of 122 participants who met all inclusion criteria and no exclusion criteria were randomized/registered to T-DXd treatment in the United States, Asia-Pacific, and Europe.

Participant flow — Overall Study
MilestoneT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
Started8240
Completed00
Not completed8240
Withdrew: Adverse event64
Withdrew: Clinical progression55
Withdrew: Death21
Withdrew: Other51
Withdrew: Progressive disease6329
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer

Confirmed objective response rate (ORR), defined as the number (percentage) of participants with complete response (CR) or partial response (PR), were assessed by blinded independent central review (BICR) based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
6 months post-dose administration to data cut off, up to 20 months
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer
percentage of participantsT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer37.8 (27.3 to 49.2)27.5 (14.6 to 43.9)
SecondaryConfirmed Objective Response Rate by Investigator Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer

Confirmed objective response rate (ORR), defined as the number (percentage) of participants with complete response (CR) or partial response (PR), were assessed by Investigator assessment based on RECIST version 1.1. CR was defined as the disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. ORR was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
From first dose administration to data cut off, up to approximately 19 months
Reported as:
Number · percentage of participants
Confirmed Objective Response Rate by Investigator Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer
percentage of participantsT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
Confirmed Objective Response Rate by Investigator Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer31.7 (21.9 to 42.9)30.0 (16.6 to 46.5)
SecondaryDuration of Response Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer

DoR, defined as time from the initial response (CR or PR) by BICR and Investigator assessment until documented tumor progression or death from any cause. DoR was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
From the first documented evidence of a response (complete or partial) until disease progression or death, up to approximately 19 months.
Reported as:
Median · months
Duration of Response Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer
monthsT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
BICR5.5 (4.2 to 8.1)5.5 (3.7 to NA)
Investigator5.6 (4.2 to 8.0)6.9 (4.9 to 9.9)
SecondaryDisease Control Rate Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) -Overexpressing Metastatic Colorectal Cancer

Disease Control Rate (DCR), defined as the proportion of subjects who achieved CR, PR, or SD for a minimum of 6 weeks during study treatment; DCR based on BICR and DCR based on Investigator assessments assessed according to RECIST version 1.1. DCR was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
From first dose administration to data cut off, up to approximately 19 months.
Reported as:
Number · percentage of participants
Disease Control Rate Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) -Overexpressing Metastatic Colorectal Cancer
percentage of participantsT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
BICR86.6 (77.3 to 93.1)85.0 (70.2 to 94.3)
Investigator89.0 (80.2 to 94.9)85.0 (70.2 to 94.3)
SecondaryClinical Benefit Rate Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) -Overexpressing Metastatic Colorectal Cancer

Clinical Benefit Rate (CBR), defined as proportion of subjects who achieved CR, PR, or SD for at least 6 months; CBR based on BICR and CBR based on Investigator assessments will both be determined based on RECIST version 1.1. CBR was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
From first dose administration to data cut off, up to approximately 19 months.
Reported as:
Number · percentage of participants
Clinical Benefit Rate Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) -Overexpressing Metastatic Colorectal Cancer
percentage of participantsT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
BICR45.1 (34.1 to 56.5)32.5 (18.6 to 49.1)
Investigator51.2 (39.9 to 62.4)42.5 (27.0 to 59.1)
SecondaryProgression Free Survival Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer

Progression Free Survival (PFS) defined as the time from date of randomization/registration until first objective radiographic tumor progression or death from any cause, based on BICR and Investigator assessment according to RECIST version 1.1. PFS was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
From randomization to data cut off, up to approximately 19 months.
Reported as:
Median · month
Progression Free Survival Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer
monthT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
BICR5.8 (4.6 to 7.0)5.5 (4.2 to 7.0)
Investigator5.8 (4.7 to 7.0)5.7 (4.2 to 8.3)
SecondaryOverall Survival Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer

Overall Survival (OS) defined as the time from date of randomization/ registration until death from any cause, according to RECIST version 1.1. OS was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
From randomization to data cut off, up to approximately 19 months.
Reported as:
Median · months
Overall Survival Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer
monthsT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
Overall Survival Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer13.4 (13.4 to 16.8)NA (NA to NA)
SecondaryPercentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer

A Treatment-emergent Adverse Events (TEAE) is defined as an AE that occurs, having been absent before the first dose of study drug or has worsened in severity or seriousness after initiating the study drug until 47 days after the last dose of the study drug. Serious AEs with an onset or worsening 48 days or more after the last dose of study drug, if considered related to study treatment. are also TEAEs. TEAEs were assessed in the Safety Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
From first dose administration to data cut off, up to approximately 19 months.
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer
percentage of participantsT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer98.8100
Other pre-specifiedChange From Baseline in Patient-Reported Outcomes (PROs) in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30)

Exploratory outcome, results not included in this submission. The QLQ-C30 is composed of both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items and no item occurs in more than 1 scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Patient questionnaires were assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
From baseline to data cut off, up to approximately 19 months.

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in Patient-Reported Outcomes (PROs) in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Colorectal Cancer 29 (QLQ-CR29)

Exploratory outcome, results not included in this submission. EORTC QLQ-CR29 is designed to be administered in addition to EORTC QLQ-C30. The EORTC QLQ-CR29 is a specific questionnaire for Colorectal Cancer. Scale from 0 to 100, A higher scale represents better function and a higher quality of life.

Time frame:
From baseline to data cut off, up to approximately 19 months

No measurements were reported for this outcome.

Other pre-specifiedPatient-Reported Outcomes (PROs) in the EuroQol Questionnaire (EQ) of 5 Dimensions (5D) on a Standardized 5- Level (5L) Descriptive Health Status Scale (EQ-5D-5L)

Exploratory outcome, results not included in this submission. The EQ-5D-5L is self-administered and consists of 2 parts, the EQ-5D-5L descriptive system and the EQ-visual analogue scale. On each dimension, a score of 1 indicates no patient problems in that dimension, 2 indicates slight problems in that dimension, 3 indicates moderate problems in that dimension, 4 indicates severe problems in that dimension and 5 indicates extreme problems in that dimension.

Time frame:
From baseline to data cut off, up to approximately 19 months

No measurements were reported for this outcome.

Other pre-specifiedPatient-Reported Outcomes (PROs) in Patient's Global Impression of Treatment Tolerability (PGI-TT)

Exploratory outcome, results not included in this submission. The PGI-TT item is included to assess how a patient perceives the overall tolerability of the study treatment over the past 7 days. This is a single-item questionnaire, and patients will rate the bother associated with any treatment-related symptoms using response options ranging from "Not at all" to "Very much".

Time frame:
From baseline to data cut off, up to approximately 19 months

No measurements were reported for this outcome.

Other pre-specifiedPatient-Reported Outcomes (PROs) in Patient Global Impression of Symptom Severity (PGIS)

Exploratory outcome, results not included in this submission. The PGIS item is included to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. This is a single-item questionnaire, and patients will choose the response that best describes the severity of their overall cancer symptoms with options ranging from "No Symptoms" to "Very Severe".

Time frame:
From baseline to data cut off, up to approximately 19 months

No measurements were reported for this outcome.

Other pre-specifiedPatient-Reported Outcomes (PROs) in Patient Global Impression of Symptom Severity (PGIC)

Exploratory outcome, results not included in this submission. The PGIC item is included to assess how a patient perceives their overall change in health status since the start of study treatment. This is a single-item questionnaire, and patients will choose from response options ranging from "Much Better" to "Much Worse".

Time frame:
From baseline to data cut off, up to approximately 19 months

No measurements were reported for this outcome.

Other pre-specifiedInpatient Healthcare Resource Utilization

Exploratory outcome, results not included in this submission. The impact of treatment and disease on healthcare resource use (including inpatient admissions, intensive care unit admissions, and length of stay in hospital) will be captured/collected in this study on an event-driven basis.

Time frame:
From baseline to data cut off, up to approximately 19 months

No measurements were reported for this outcome.

SecondarySerum Concentration of T-DXd

Descriptive statistics will be provided for serum concentration data of T-DXd, DXd, and total anti-HER2 antibody. Serum concentrations were assessed in the Pharmacokinetics Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
C1D1 (Before infusion (BI), end of infusion (EOI) and 5 hours after infusion), C1D8 (7 days after infusion), C1D15 (14 days after infusion), C2D1 (BI and EOI), C3D1 (BI and EOI), C4D1, (BI and EOI), C6D1 (BI and EOI)
Reported as:
Geometric mean · ug/L
Serum Concentration of T-DXd
ug/LT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
C1D1 - Before InfusionNA ± NANA ± NA
C1D1 - End of Infusion118452.77 ± 27.5134613.79 ± 18.1
C1D1 - 5Hrs After Infusion123433.28 ± 23.0142399.71 ± 19.8
C1D8 - 7 Days After Infusion22261.67 ± 38.928142.80 ± 51.5
C1D15 - 14 Days After Infusion8092.08 ± 61.711396.97 ± 60.3
C2D1 - Before Infusion2827.01 ± 118.84420.63 ± 73.0
C2D1 - End of Infusion109777.43 ± 67.2135637.46 ± 22.2
C3D1 - Before Infusion4823.41 ± 83.67543.17 ± 74.3
C3D1 - End of Infusion122218.96 ± 25.8139264.52 ± 24.7
C4D1 - Before Infusion5846.34 ± 89.511013.81 ± 51.8
C4D1 - End of Infusion124240.37 ± 23.4134129.68 ± 30.3
C6D1 - Before Infusion7507.28 ± 74.510793.89 ± 59.0
C6D1 - End of Infusion117769.64 ± 25.335753.88 ± 1079.6
SecondarySerum Concentration of Total Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Antibody

Descriptive statistics will be provided for serum concentration data of T-DXd, DXd, and total anti-HER2 antibody. Serum concentrations were assessed in the Pharmacokinetics Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
C1D1 (Before infusion (BI), end of infusion (EOI) and 5 hours after infusion), C1D8 (7 days after infusion), C1D15 (14 days after infusion), C2D1 (BI and EOI), C3D1 (BI and EOI), C4D1, (BI and EOI), C6D1 (BI and EOI)
Reported as:
Geometric mean · ug/L
Serum Concentration of Total Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Antibody
ug/LT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
C1D1 - Before Infusion5211.18 ± 388.511934.79 ± 2058.9
C1D1 - End of Infusion110871.93 ± 28.8121423.37 ± 20.3
C1D1 - 5Hrs After Infusion107339.74 ± 23.4124274.05 ± 23.0
C1D8 - 7 Days After Infusion27646.77 ± 40.332741.77 ± 49.9
C1D15 - 14 Days After Infusion10920.88 ± 71.714293.10 ± 63.0
C2D1 - Before Infusion3723.58 ± 123.14841.90 ± 107.5
C2D1 - End of Infusion106755.21 ± 66.0127427.43 ± 23.2
C3D1 - Before Infusion6286.00 ± 93.29100.39 ± 90.0
C3D1 - End of Infusion114763.30 ± 22.8134111.33 ± 19.5
C4D1 - Before Infusion7388.01 ± 101.814007.95 ± 67.2
C4D1 - End of Infusion113711.08 ± 21.5133956.61 ± 30.5
C6D1 - Before Infusion9033.08 ± 94.913535.33 ± 73.5
C6D1 - End of Infusion104328.76 ± 35.437091.52 ± 816.2
SecondarySerum Concentration of Active Metabolite MAAA-1181a

Descriptive statistics will be provided for serum concentration data of T-DXd, DXd, and total anti-HER2 antibody. Serum concentrations were assessed in the Pharmacokinetics Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
C1D1 (Before infusion (BI), end of infusion (EOI) and 5 hours after infusion), C1D8 (7 days after infusion), C1D15 (14 days after infusion), C2D1 (BI and EOI), C3D1 (BI and EOI), C4D1, (BI and EOI), C6D1 (BI and EOI)
Reported as:
Geometric mean · pg/mL
Serum Concentration of Active Metabolite MAAA-1181a
pg/mLT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
C1D1 - Before InfusionNA ± NANA ± NA
C1D1 - End of Infusion4101.40 ± 56.64313.38 ± 45.3
C1D1 - 5Hrs After Infusion12063.71 ± 52.815773.44 ± 39.0
C1D8 - 7 Days After Infusion1372.33 ± 75.81761.02 ± 67.1
C1D15 - 14 Days After Infusion475.30 ± 62.4602.43 ± 54.1
C2D1 - Before Infusion209.06 ± 74.6291.07 ± 55.4
C2D1 - End of Infusion1474.48 ± 71.21649.91 ± 65.8
C3D1 - Before Infusion279.56 ± 64.0427.33 ± 89.5
C3D1 - End of Infusion1559.93 ± 52.61647.92 ± 53.1
C4D1 - Before Infusion284.38 ± 81.4494.17 ± 61.2
C4D1 - End of Infusion1448.53 ± 48.51404.67 ± 54.1
C6D1 - Before Infusion332.07 ± 81.3578.72 ± 55.8
C6D1 - End of Infusion1182.53 ± 36.81512.25 ± 32.3
SecondaryPercentage of Participants Positive for Treatment-emergent Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (NAb) in Participants Who Were Administered T-DXd

Immunogenicity will be assessed through characterization of incidence and titer of Anti-drug Antibodies (ADAs), the number and percentage of subjects positive for NAb of T-DXd by dose level will also be determined. ADAs and NAbs were assessed in the Immunogenicity Analysis Set at data cut-off date of 01 Nov 2022.

Time frame:
From baseline to data cut off, up to approximately 19 months
Reported as:
Number · percentage of participants
Percentage of Participants Positive for Treatment-emergent Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (NAb) in Participants Who Were Administered T-DXd
percentage of participantsT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
ADA1.30
NAb00

Adverse events

Collected over Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up to approximately 44 months. For Final Results, data was collected up until 04 Dec 2024.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T-DXd 5.4 mg/kg Q3W26/83 (31.3%)21/83 (25.3%)81/83 (97.6%)
T-DXd 6.4 mg/kg Q3W13/39 (33.3%)12/39 (30.8%)38/39 (97.4%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
Neutrophil count decreasedInvestigations0/832/39
NauseaGastrointestinal disorders3/830/39
AnaemiaBlood and lymphatic system disorders2/831/39
Febrile neutropeniaBlood and lymphatic system disorders2/831/39
ThrombocytopeniaBlood and lymphatic system disorders0/831/39
Small intestinal obstructionGastrointestinal disorders2/831/39
Abdominal painGastrointestinal disorders0/831/39
DiarrhoeaGastrointestinal disorders0/831/39
GastritisGastrointestinal disorders0/831/39
Intestinal obstructionGastrointestinal disorders0/831/39
Most frequent other events
Showing 10 of 45
Most frequent other events
EventT-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3W
NauseaGastrointestinal disorders49/8322/39
AnaemiaBlood and lymphatic system disorders22/8316/39
Neutrophil count decreasedInvestigations18/8316/39
Platelet count decreasedInvestigations18/8312/39
Decreased appetiteMetabolism and nutrition disorders25/836/39
DiarrhoeaGastrointestinal disorders19/8311/39
AlopeciaSkin and subcutaneous tissue disorders19/8311/39
ConstipationGastrointestinal disorders20/836/39
VomitingGastrointestinal disorders17/833/39
AstheniaGeneral disorders17/836/39

Baseline characteristics

The baseline demographic characteristics were assessed in the Full Analysis Set, which included 1 participant who was randomized/registered to T-DXd 6.4 mg/kg Q3W but actually received T-DXd 5.4 mg/kg Q3W.

Age, Categorical
Age, Categorical(Participants)T-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3WTotal
<=18 years000
Between 18 and 65 years542377
>=65 years281745
Age, Continuous
Age, Continuous(years)T-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3WTotal
Mean58.5 ± 13.0561.1 ± 12.1359.3 ± 12.77
Sex: Female, Male
Sex: Female, Male(Participants)T-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3WTotal
Female372158
Male451964
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)T-DXd 5.4 mg/kg Q3WT-DXd 6.4 mg/kg Q3WTotal
White351550
Black or African American000
Asian422466
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Other516
08

Study locations

63 sites
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • Norton Cancer Institute Audubon
    Louisville, Kentucky 40217, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Memorial Sloan Kettering Cancer Center (MSKCC)
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Sarah Cannon (Tennessee Oncology - Nashville)
    Nashville, Tennessee 37203, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Flinders Medical Centre (FMC)
    Bedford Park, Australia
  • Blacktown Hospital
    Blacktown, Australia
  • Royal Brisbane & Women's Hospital
    Brisbane, Australia
  • Monash Medical Centre
    Clayton, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Australia
  • UCL St-Luc
    Brussels, Belgium
  • UZ Antwerpen
    Edegem, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, Belgium
  • Hopital Jean Minjoz
    Besançon, France
  • Hopital Edouard Herriot
    Lyon, France
  • ICM-Val d'Aurelle
    Montpellier, France
  • University Hospital of nantes
    Nantes, France
  • Centre Antoine Lacassagne
    Nice, France
  • Hopital St Antoine
    Paris, France
  • Centre de Lutte Contre le Cancer CLCC - Institut Curie
    Saint-Cloud, France
  • Chu Toulouse
    Toulouse, France
  • Asst Grande Ospedale Metropolitano Niguarda
    Milan, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, Italy
  • Istituto Oncologico Veneto Irccs
    Padova, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, Italy
  • Aienda Ospedaliera San Camillo Forlanini
    Rome, Italy
  • Azienda ULSS 8 Berica
    Vicenza, Italy
  • Aichi Cancer Center Hospital
    Aichi, Japan
  • National Cancer Center Hospital East
    Chiba, Japan
  • National Hospital Organization Shikoku Cancer Center
    Ehime, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, Japan
  • Hokkaido University Hospital
    Hokkaido, Japan
  • Kanagawa Cancer Center
    Kanagawa, Japan
  • Kindai University Hospital
    Osaka, Japan
  • National Hospital Organization Osaka National Hospital
    Osaka, Japan
  • National Cancer Center Hospital
    Tokyo, Japan
  • The Cancer Institute Hospital of JFCR
    Tokyo, Japan
  • National Cancer Center (NCC)
    Goyang-si, South Korea
  • Seoul National University Bundang Hospital
    Gyeonggi-do, South Korea
  • Asan Medical Center
    Seoul, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • Severance Hospital Yonsei University Health System
    Seoul, South Korea
  • Hospital Clinico y Provincial de Barcelona
    Barcelona, Spain
  • Hospital Universitari Vall dHebron
    Barcelona, Spain
  • Clinica Universitaria de Navarra - Madrid
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Clinica Universitaria de Navarra
    Pamplona, Spain
  • Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH
    Kaohsiung City, Taiwan
  • China Medical University Hospital
    Taichung, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Chang Gung Memorial Hospital CGMH - Kaohsiung Branch
    Taoyuan, Taiwan
  • Chang Gung Memorial Hospital-LinKou
    Taoyuan, Taiwan
  • Beatson Glasgow
    Glasgow, United Kingdom
  • The Royal Marsden Hospital
    London, United Kingdom
  • UCLH Trust
    London, United Kingdom
  • The Christie
    Manchester, United Kingdom
  • The Royal Marsden Hospital
    Sutton, United Kingdom
09

References and documents

Publications

  • Raghav K. Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: a plain language summary of the DESTINY-CRC02 study. Future Oncol. 2026 Jan;22(2):123-135. doi: 10.1080/14796694.2025.2606418. Epub 2026 Jan 5. PubMed 41487064 ↗
  • Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, Yoshino T. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024 Sep;25(9):1147-1162. doi: 10.1016/S1470-2045(24)00380-2. Epub 2024 Aug 5. PubMed 39116902 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https:// vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Nov 2022, 19 months.

Results were first posted in Jan 2024, 1 year 2 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 19 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2021
First posted
Feb 9, 2021
StartActual
Mar 5, 2021
Primary completionActual
Nov 1, 2022
CompletionActual
Dec 4, 2024
Results first posted
Jan 2, 2024
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04744831
Lead sponsor
Daiichi Sankyo
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Feb 9, 2021
Start date
Mar 5, 2021
Primary completion
Nov 1, 2022
Completion
Dec 4, 2024
Results posted
Jan 2, 2024
Last update
Jan 14, 2026

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion